12:00 AM
Feb 25, 2013
 |  BioCentury  |  Emerging Company Profile

Longevity: Internal Improvements

Longevity stabilizing peptides internally with non-natural beta amino acids

A handful of companies are using non-natural amino acids to improve the pharmacokinetic and metabolic profiles of peptides and proteins, but such modifications often alter the surface of the molecule, which can affect its binding profile and other characteristics.

Longevity Biotech Inc. says its rational approach of using non-natural beta amino acids to modify the internal structure of peptides and proteins should be better at preserving a molecule's native biological properties and have lower risk of causing off-target binding and toxicity.

Longevity uses its computational protein design platform to predict the sites in an amino acid sequence where insertion of non-natural beta amino acids could alter a peptide or protein's internal structure to achieve the desired pharmacokinetic and metabolic profile. Longevity then synthesizes the candidate molecules, which it calls Hybridtides.

In general, methods for incorporating non-natural amino acids into peptides and proteins are intended to make them resistant to proteolytic degradation, improve their structural stability, and confer new functionality.

Three things differentiate Hybridtides from other approaches: the type of non-natural amino acids...

Read the full 841 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >